
Frank Erhard Uschner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4196287/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. Journal of Hepatology, 2021, 74, 1097-1108.	3.7	149
2	Seven weeks of Western diet in apolipoprotein-E-deficient mice induce metabolic syndrome and non-alcoholic steatohepatitis with liver fibrosis. Scientific Reports, 2015, 5, 12931.	3.3	127
3	Circulating microbiome in blood of different circulatory compartments. Gut, 2019, 68, 578-580.	12.1	120
4	Quantification of Liver Fibrosis at T1 and T2 Mapping with Extracellular Volume Fraction MRI: Preclinical Results. Radiology, 2018, 288, 748-754.	7.3	96
5	Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet Gastroenterology and Hepatology, 2020, 5, 31-41.	8.1	75
6	Granulocyte-colony stimulating factor (G-CSF) to treat acute-on-chronic liver failure: A multicenter randomized trial (GRAFT study). Journal of Hepatology, 2021, 75, 1346-1354.	3.7	69
7	Statins improve NASH via inhibition of RhoA and Ras. American Journal of Physiology - Renal Physiology, 2016, 311, G724-G733.	3.4	61
8	Janus-kinase-2 relates directly to portal hypertension and to complications in rodent and human cirrhosis. Gut, 2017, 66, 145-155.	12.1	58
9	Rationale for the use of statins in liver disease. American Journal of Physiology - Renal Physiology, 2017, 312, G407-G412.	3.4	52
10	Trends and the course of liver cirrhosis and its complications in Germany: Nationwide population-based study (2005 to 2018). Lancet Regional Health - Europe, The, 2022, 12, 100240.	5.6	50
11	Differential inflammasome activation predisposes to acute-on-chronic liver failure in human and experimental cirrhosis with and without previous decompensation. Gut, 2021, 70, gutjnl-2019-320170.	12.1	47
12	Cardiodynamic state is associated with systemic inflammation and fatal acuteâ€onâ€chronic liver failure. Liver International, 2020, 40, 1457-1466.	3.9	46
13	Statins activate the canonical hedgehog-signaling and aggravate non-cirrhotic portal hypertension, but inhibit the non-canonical hedgehog signaling and cirrhotic portal hypertension. Scientific Reports, 2015, 5, 14573.	3.3	45
14	Acute decompensation boosts hepatic collagen type III deposition and deteriorates experimental and human cirrhosis. Hepatology Communications, 2018, 2, 211-222.	4.3	45
15	Role of portal venous platelet activation in patients with decompensated cirrhosis and TIPS. Gut, 2020, 69, 1535-1536.	12.1	42
16	Compartmentalization of Immune Response and Microbial Translocation in Decompensated Cirrhosis. Frontiers in Immunology, 2019, 10, 69.	4.8	40
17	The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats. Scientific Reports, 2018, 8, 9372.	3.3	39
18	Two-dimensional shear wave elastography predicts survival in advanced chronic liver disease. Gut, 2022, 71, 402-414.	12.1	39

FRANK ERHARD USCHNER

#	Article	IF	CITATIONS
19	Combination of CCl ₄ with alcoholic and metabolic injuries mimics human liver fibrosis. American Journal of Physiology - Renal Physiology, 2019, 317, G182-G194.	3.4	37
20	Interplay of Matrix Stiffness and c-SRC in Hepatic Fibrosis. Frontiers in Physiology, 2015, 6, 359.	2.8	35
21	Hemodynamic Effects of the Non-Peptidic Angiotensin-(1-7) Agonist AVE0991 in Liver Cirrhosis. PLoS ONE, 2015, 10, e0138732.	2.5	29
22	Systemic MCP-1 Levels Derive Mainly From Injured Liver and Are Associated With Complications in Cirrhosis. Frontiers in Immunology, 2020, 11, 354.	4.8	27
23	Left Ventricular Longitudinal Contractility Predicts Acuteâ€onâ€Chronic Liver Failure Development and Mortality After Transjugular Intrahepatic Portosystemic Shunt. Hepatology Communications, 2019, 3, 340-347.	4.3	26
24	Rho-kinase inhibitor coupled to peptide-modified albumin carrier reduces portal pressure and increases renal perfusion in cirrhotic rats. Scientific Reports, 2019, 9, 2256.	3.3	26
25	Quantitative liver MRI including extracellular volume fraction for non-invasive quantification of liver fibrosis: a prospective proof-of-concept study. Gut, 2018, 67, 593-594.	12.1	25
26	Dynamic human liver proteome atlas reveals functional insights into disease pathways. Molecular Systems Biology, 2022, 18, e10947.	7.2	22
27	The multikinase inhibitor regorafenib decreases angiogenesis and improves portal hypertension. Oncotarget, 2018, 9, 36220-36237.	1.8	20
28	Novel Rat Model of Repetitive Portal Venous Embolization Mimicking Human Non-Cirrhotic Idiopathic Portal Hypertension. PLoS ONE, 2016, 11, e0162144.	2,5	16
29	Mouse and Rat Models of Induction of Hepatic Fibrosis and Assessment of Portal Hypertension. Methods in Molecular Biology, 2017, 1627, 91-116.	0.9	16
30	Hepatic inflammasome activation as origin of Interleukin-1α and Interleukin-1β in liver cirrhosis. Gut, 2021, 70, 1799-1800.	12.1	14
31	The Role of Macrophage-Inducible C-Type Lectin in Different Stages of Chronic Liver Disease. Frontiers in Immunology, 2020, 11, 1352.	4.8	13
32	Quantification of liver fibrosis: extracellular volume fraction using an MRI bolus-only technique in a rat animal model. European Radiology Experimental, 2019, 3, 22.	3.4	12
33	Sex specificity of kidney markers to assess prognosis in cirrhotic patients with TIPS. Liver International, 2020, 40, 186-193.	3.9	12
34	TGR(mREN2)27 rats develop non-alcoholic fatty liver disease-associated portal hypertension responsive to modulations of Janus-kinase 2 and Mas receptor. Scientific Reports, 2019, 9, 11598.	3.3	10
35	Recent Advances in Practical Methods for Liver Cell Biology: A Short Overview. International Journal of Molecular Sciences, 2020, 21, 2027.	4.1	10
36	Combination of phosphodiesteraseâ€5â€inhibitors and beta blockers improves experimental portal hypertension and erectile dysfunction. Liver International, 2020, 40, 2228-2241.	3.9	9

FRANK ERHARD USCHNER

#	Article	IF	CITATIONS
37	Interleukin-22 in acute-on-chronic liver failure: A matter of ineffective levels, receptor dysregulation or defective signalling?. Journal of Hepatology, 2020, 73, 980-982.	3.7	8
38	Variation in Bile Microbiome by the Etiology of Cholestatic Liver Disease. Liver Transplantation, 2020, 26, 1652-1657.	2.4	8
39	β-Arrestin2 is increased in liver fibrosis in humans and rodents. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 27082-27084.	7.1	8
40	Pathophysiological role of prostanoids in coagulation of the portal venous system in liver cirrhosis. PLoS ONE, 2019, 14, e0222840.	2.5	7
41	Short-Term Western Diet Aggravates Non-Alcoholic Fatty Liver Disease (NAFLD) With Portal Hypertension in TCR(mREN2)27 Rats. International Journal of Molecular Sciences, 2020, 21, 3308.	4.1	7
42	Impact of sleeve gastrectomy and dietary change on metabolic and hepatic function in an obesity rat model - Experimental research. International Journal of Surgery, 2020, 75, 139-147.	2.7	7
43	Extrahepatic Surgery in Cirrhosis Significantly Increases Portal Pressure in Preclinical Animal Models. Frontiers in Physiology, 2021, 12, 720898.	2.8	7
44	Pulmonary impairment independently determines mortality in critically ill patients with acuteâ€onâ€chronic liver failure. Liver International, 2023, 43, 180-193.	3.9	7
45	"Tipping" extracellular matrix remodeling towards regression of liver fibrosis: novel concepts. Minerva Gastroenterology, 2017, 64, 51-61.	0.5	6
46	Variceal bleeding has increased mortality compared to nonvariceal bleeding only in males. European Journal of Gastroenterology and Hepatology, 2020, Publish Ahead of Print, .	1.6	3
47	Role of circulating angiogenin levels in portal hypertension and TIPS. PLoS ONE, 2021, 16, e0256473.	2.5	2
48	Possible Treatment Strategies for Portal Hypertension in Liver Cirrhosis. Current Hepatology Reports, 2016, 15, 271-279.	0.9	0
49	Animal Models When Examining the Gut-Liver Axis. , 2019, , 235-264.		0